guanylin and Crohn-Disease

guanylin has been researched along with Crohn-Disease* in 1 studies

Other Studies

1 other study(ies) available for guanylin and Crohn-Disease

Article	Year
Pituitary adenylate cyclase-activating polypeptide: a potent activator of human intestinal ion transport. Annals of the New York Academy of Sciences, 1996, Dec-26, Volume: 805 To investigate the effects of PACAP-27 on electrolyte transport across the isolated human intestinal mucosa, changes in short-circuit current (Isc) were measured in Ussing chamber experiments. Serosally added PACAP-27 increased Isc in a concentration-dependent manner, eliciting a similar maximal effect in both the jejunal and the colonic mucosa. Bumetanide inhibited Isc responses, indicating stimulation of Cl- secretion. The potency and efficacy of PACAP-27 were comparable to those of VIP, suggesting that both peptides activate intestinal secretion by way of a common receptor located in the basolateral membrane of the intestinal epithelium. Topics: Colon; Crohn Disease; Dose-Response Relationship, Drug; Electrolytes; Gastrointestinal Hormones; Humans; In Vitro Techniques; Intestinal Mucosa; Jejunum; Membrane Potentials; Natriuretic Peptides; Neuropeptides; Neurotransmitter Agents; Peptides; Pituitary Adenylate Cyclase-Activating Polypeptide; Tetrodotoxin; Vasoactive Intestinal Peptide	1996

Article

Year

Pituitary adenylate cyclase-activating polypeptide: a potent activator of human intestinal ion transport.

Annals of the New York Academy of Sciences, 1996, Dec-26, Volume: 805

To investigate the effects of PACAP-27 on electrolyte transport across the isolated human intestinal mucosa, changes in short-circuit current (Isc) were measured in Ussing chamber experiments. Serosally added PACAP-27 increased Isc in a concentration-dependent manner, eliciting a similar maximal effect in both the jejunal and the colonic mucosa. Bumetanide inhibited Isc responses, indicating stimulation of Cl- secretion. The potency and efficacy of PACAP-27 were comparable to those of VIP, suggesting that both peptides activate intestinal secretion by way of a common receptor located in the basolateral membrane of the intestinal epithelium.

Topics: Colon; Crohn Disease; Dose-Response Relationship, Drug; Electrolytes; Gastrointestinal Hormones; Humans; In Vitro Techniques; Intestinal Mucosa; Jejunum; Membrane Potentials; Natriuretic Peptides; Neuropeptides; Neurotransmitter Agents; Peptides; Pituitary Adenylate Cyclase-Activating Polypeptide; Tetrodotoxin; Vasoactive Intestinal Peptide

1996